LOTEMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTEMAX (LOTEMAX).
Lotemax (loteprednol etabonate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2 activity, thereby reducing arachidonic acid release and subsequent synthesis of prostaglandins and leukotrienes.
| Metabolism | Primarily hydrolyzed by esterases in ocular tissues to an inactive metabolite; systemic absorption minimal with hepatic metabolism via CYP450 enzymes (minor). |
| Excretion | Approximately 80% of the dose is excreted in the feces via biliary elimination as parent drug and metabolites, and about 20% is excreted in the urine as metabolites. |
| Half-life | The terminal elimination half-life is approximately 1.5–3 hours. Due to rapid clearance, systemic accumulation is minimal with topical ocular administration. |
| Protein binding | Loteprednol etabonate is approximately 80% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution is approximately 0.5–1 L/kg, suggesting distribution into total body water. Due to high lipophilicity, it partitions into ocular tissues. |
| Bioavailability | Systemic bioavailability after topical ocular administration is very low (<1%) due to extensive first-pass metabolism and poor absorption across the cornea. Oral bioavailability has not been characterized as it is not administered orally. |
| Onset of Action | Clinical effect (reduction of ocular inflammation) typically begins within 2–4 hours after topical ocular instillation. |
| Duration of Action | Duration of action is approximately 6–8 hours after a single dose, corresponding to the dosing interval of every 4–6 hours for acute conditions. |
One drop of 0.5% ophthalmic suspension into the affected eye(s) four times daily for up to 2 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific dose adjustment recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no specific weight-based guidelines available. |
| Geriatric use | No specific dose adjustment required; use same as adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOTEMAX (LOTEMAX).
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not determined. Corticosteroids are excreted in breast milk in small amounts after systemic administration; ocular administration yields negligible systemic exposure. Caution advised; consider risk-benefit. |
| Teratogenic Risk | Category C: No adequate studies in pregnant women. In animal studies, topical ocular corticosteroids caused teratogenicity at maternally toxic doses, including cleft palate, umbilical hernia, and delayed ossification. Risk cannot be ruled out; use only if potential benefit justifies risk. First trimester: avoid if possible. Second/third trimester: limited data, but systemic absorption is low with ocular administration. |
■ FDA Black Box Warning
Not applicable.
| Serious Effects |
["Active ocular infection (fungal, viral, bacterial)","Hypersensitivity to loteprednol or any component","Epithelial herpes simplex keratitis (dendritic keratitis)"]
| Precautions | ["Prolonged use may lead to elevated intraocular pressure (IOP); monitor IOP.","May increase risk of secondary ocular infections; caution in herpetic infections.","Cataract formation with long-term use.","Delayed wound healing.","May cause thinning of cornea and sclera."] |
Loading safety data…
| Fetal Monitoring | Monitor intraocular pressure (IOP) during prolonged use; pregnancy may alter IOP. Check for cataract formation or secondary infections. Assess fetal growth and development if used chronically in pregnancy. |
| Fertility Effects | No specific human data; animal studies show no impairment of fertility at clinically relevant doses. Corticosteroids may affect hormonal balance theoretically, but no evidence of significant impact with ocular use. |